Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.57 USD
+0.11 (0.29%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Cash flow Statements
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 281.59 | 202.13 | 402.71 | 129.09 | -72.24 |
Depreciation/Amortization & Depletion | 85.84 | 58.59 | 8.90 | 18.26 | 4.08 |
Net Change from Assets/Liabilities | -38.67 | -88.45 | 2.24 | -107.85 | -54.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 59.81 | 67.84 | -114.41 | 15.96 | 37.27 |
Net Cash From Operating Activities | 388.57 | 240.11 | 299.44 | 55.45 | -85.42 |
Property & Equipment | -15.29 | 21.20 | -1.46 | -1.43 | -4.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -999.12 | 0.00 | 0.00 | 0.00 |
Investments | -81.62 | 490.92 | -404.83 | 79.78 | -1.51 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -96.91 | -487.01 | -406.29 | 78.35 | -5.55 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -394.50 | -185.95 | -337.52 | -86.72 | -185.77 |
Issuance (Repayment) of Debt | -13.48 | 555.43 | 415.81 | -19.56 | 339.27 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -7.10 | -0.42 | 0.00 | -0.28 |
Net Cash from Financing Activities | -407.99 | 362.37 | 77.87 | -106.28 | 153.22 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -116.33 | 115.48 | -28.98 | 27.52 | 62.24 |
Cash at Beginning of Period | 234.70 | 119.22 | 148.20 | 120.68 | 58.44 |
Cash at End of Period | 118.37 | 234.70 | 119.22 | 148.20 | 120.68 |
Diluted Net EPS | 2.10 | 1.44 | 2.74 | 0.91 | -0.50 |
Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 281.59 | 196.21 | 114.37 | 39.62 |
Depreciation/Amortization & Depletion | NA | 85.84 | 65.81 | 42.40 | 21.38 |
Net Change from Assets/Liabilities | NA | -38.67 | -15.15 | -37.07 | 13.81 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 59.81 | 39.36 | 34.11 | 12.16 |
Net Cash From Operating Activities | NA | 388.57 | 286.22 | 153.81 | 86.96 |
Property & Equipment | NA | -15.29 | -12.70 | -9.75 | -11.38 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -81.62 | -75.92 | 4.59 | -48.79 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -96.91 | -88.62 | -5.17 | -60.16 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -394.50 | -144.58 | -148.69 | -151.13 |
Issuance (Repayment) of Debt | NA | -13.48 | -13.48 | -13.48 | -13.48 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -407.99 | -158.07 | -162.17 | -164.61 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -116.33 | 39.53 | -13.53 | -137.81 |
Cash at Beginning of Period | NA | 234.70 | 234.70 | 234.70 | 234.70 |
Cash at End of Period | NA | 118.37 | 274.23 | 221.17 | 96.88 |
Diluted Net EPS | NA | 0.64 | 0.61 | 0.56 | 0.29 |